-
公开(公告)号：US11078262B2
公开(公告)日：2021-08-03
申请号：US11742350
申请日：2007-04-30
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
-
2.发明申请公开(公告)号：US20080268051A1
公开(公告)日：2008-10-30
申请号：US11742350
申请日：2007-04-30
IPC分类号： A61K9/00 , A61P27/02 , A61K38/00 , A61K31/711 , A61K39/395
CPC分类号： C07K16/22 , A61K9/0048 , A61K9/08 , A61K38/39 , A61K47/34 , A61K2039/505 , C07K2317/24 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/332 , C12N2320/32
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
摘要翻译： 提供了抗血管生成组合物，以及使用这些组合物的方法，其可用于注射到人眼玻璃体中。 这样的组合物包括以治疗有效量存在的MAAC溶液或颗粒，粘度诱导组分和水性载体组分。 组合物在约25℃下的粘度为0.1 /秒的剪切速率为至少约10cps或约100cps。 在优选的实施方案中，25℃下的粘度在约80,000cps至约300,000cps的范围内。
-
3.发明授权Methods and compositions for intraocular administration to treat ocular conditions 有权用于眼内给药以治疗眼部病症的方法和组合物公开(公告)号：US08642067B2
公开(公告)日：2014-02-04
申请号：US11695527
申请日：2007-04-02
IPC分类号： A61F2/00
CPC分类号： A61K31/404 , A61K9/0048 , A61K31/33 , A61K31/728 , A61K47/14 , A61K47/36 , A61K2300/00
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
摘要翻译： 提供了抗血管生成组合物，以及使用这些组合物的方法，其可用于注射到人眼玻璃体中。 这样的组合物可以包括TKI组分溶液或以治疗有效量存在的颗粒，粘度诱导组分和水性载体组分。 组合物在约25℃下的粘度为0.1 /秒的剪切速率为至少约10cps或约100cps。 在优选的实施方案中，25℃下的粘度在约80,000cps至约300,000cps的范围内。
-
公开(公告)号：US08846094B2
公开(公告)日：2014-09-30
申请号：US11828561
申请日：2007-07-26
IPC分类号： A61K9/14 , A61K31/56 , A61K47/02 , A61K47/36 , A61K47/40 , A61K31/715 , A61K47/34 , A61K31/573 , A61K9/00
CPC分类号： A61K9/0019 , A61K9/0048 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/715 , A61K47/02 , A61K47/34 , A61K47/36 , A61K47/40
摘要： Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.
摘要翻译： 提供使用这种组合物的粘性制剂和方法，其可用于肌肉内和关节内注射以治疗外周病症。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中，粘度在25℃下以0.1 /秒的剪切速率在约140,000cps至约280,000cps的范围内。组合物有利地将曲安奈德颗粒悬浮较长时间。
-
公开(公告)号：US20080269181A1
公开(公告)日：2008-10-30
申请号：US12172194
申请日：2008-07-11
CPC分类号： A61K31/58 , A61K9/0048 , A61K31/573 , A61K47/36
摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。 组合物有利地将颗粒悬浮长时间。
-
公开(公告)号：US08569272B2
公开(公告)日：2013-10-29
申请号：US12172194
申请日：2008-07-11
CPC分类号： A61K31/58 , A61K9/0048 , A61K31/573 , A61K47/36
摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。 组合物有利地将颗粒悬浮长时间。
-
7.发明申请METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS 有权用于治疗眼睛条件的室间管理的方法和组合公开(公告)号：US20080241252A1
公开(公告)日：2008-10-02
申请号：US11695527
申请日：2007-04-02
CPC分类号： A61K31/404 , A61K9/0048 , A61K31/33 , A61K31/728 , A61K47/14 , A61K47/36 , A61K2300/00
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
摘要翻译： 提供了抗血管生成组合物，以及使用这些组合物的方法，其可用于注射到人眼玻璃体中。 这样的组合物可以包括TKI组分溶液或以治疗有效量存在的颗粒，粘度诱导组分和水性载体组分。 组合物在约25℃下的粘度为0.1 /秒的剪切速率为至少约10cps或约100cps。 在优选的实施方案中，25℃下的粘度在约80,000cps至约300,000cps的范围内。
-
8.发明申请公开(公告)号：US20090196905A1
公开(公告)日：2009-08-06
申请号：US12026736
申请日：2008-02-06
申请人： Lon T. Spada , Wendy M. Blanda , Marianne M. Do , Scott M. Whitcup , Patrick M. Hughes , Michael R. Robinson
发明人： Lon T. Spada , Wendy M. Blanda , Marianne M. Do , Scott M. Whitcup , Patrick M. Hughes , Michael R. Robinson
CPC分类号： A61K38/13 , A61F9/0017 , A61F2210/0004
摘要： Methods of treating ocular diseases and conditions using biodegradable ocular implants containing cyclosporine to inhibit mitochondrial permeability transition pore formation are disclosed.
摘要翻译： 公开了使用含有环孢菌素的生物降解性眼部植入物治疗眼部疾病和病症以抑制线粒体通透性转换孔形成的方法。
-
9.发明申请METHOD FOR DETERMINING OPTIMUM INTRAOCULAR LOCATIONS FOR DRUG DELIVERY IMPLANT 失效用于确定药物递送植入物的最佳内部位置的方法公开(公告)号：US20080181929A1
公开(公告)日：2008-07-31
申请号：US11948411
申请日：2007-11-30
申请人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
发明人： Michael R. Robinson , Joan-En Chang-Lin , Devin F. Welty , Scott M. Whitcup , Patrick M. Hughes
CPC分类号： A61K39/3955 , A61F9/0017 , A61K9/0048 , A61K31/573 , A61K31/58
摘要： A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
摘要翻译： 用于确定用于放置用于治疗眼部病症的眼内植入物的最佳位置的方法，特别是由可生物降解的聚合物和用于治疗视网膜组织的治疗剂组成的植入物。
-
公开(公告)号：US20140302007A1
公开(公告)日：2014-10-09
申请号：US13466806
申请日：2012-05-08
申请人： Wendy M. Blanda , Rober K. Aoki , Terrence J. Hunt , Patrick M. Hughes , James N. Chang , Scott M. Whitcup , Michael R. Robinson
发明人： Wendy M. Blanda , Rober K. Aoki , Terrence J. Hunt , Patrick M. Hughes , James N. Chang , Scott M. Whitcup , Michael R. Robinson
CPC分类号： A61K38/4893 , A61K9/0019 , A61K9/0024 , A61K47/36 , C12Y304/24069
摘要： Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
摘要翻译： 用透明质酸载体配制的肉毒杆菌神经毒素，肉毒杆菌毒素在皮下位置的驻留时间增加，肉毒杆菌毒素诱导的并发症或副作用较少。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.036 秒)
